History

In 2006, Friends of Cancer Research, a cancer non-profit organization, established a working group composed of advocacy groups and members from their Scientific Advisory Board and beyond to explore scientific, medical, and policy issues relevant to assessing the benefits and risks of prescription drugs. The working group focused on examining how upcoming legislation and proposed changes to current policy will impact patients from a regulatory perspective.

Chaired by Dr. Robert C. Young, President of Fox Chase Cancer Center, the working group formulated recommendations resulting in the report "Drug Safety & Drug Efficacy: Two Sides of The Same Coin."  The recommendations aim to strengthen the FDA through increased resources, personnel, training, enhanced product surveillance and data collection, and to promote advancement of the agency’s scientific foundation.

While the working group was originally convened by Friends of Cancer Research, the report comes from the broader biomedical community. A full list of authors is available on the Authors page of this extended website for the report.